Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Apprentissage de la sécurité sociale dans le système cérébral d'ocytocine

10 juin 2026 mis à jour par: Angela Fang, University of Washington
Les chercheurs mènent cette étude de recherche pour examiner si l'ocytocine améliore l'apprentissage de la sécurité sociale (apprentissage de la sécurité grâce à l'expérience d'un autre individu) chez les personnes atteintes de trouble d'anxiété sociale (TAS) par rapport aux volontaires sains. L'ocytocine est une hormone qui peut également agir comme messager chimique dans le cerveau. L'ocytocine joue un rôle dans un certain nombre de fonctions, y compris la réponse à la peur et les interactions sociales. Dans cette étude, les chercheurs souhaitent comparer les effets des vaporisateurs nasaux d'ocytocine et de placebo chez des adultes souffrant de TAS et des adultes en bonne santé. Cette étude de recherche comparera un vaporisateur nasal d'ocytocine à un vaporisateur nasal placebo. Environ 120 personnes participeront à cette étude de recherche, toutes à l'Université de Washington (UW).

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

L'objectif de la présente étude est d'examiner le rôle potentiel de l'ocytocine dans l'amélioration de l'apprentissage social dans le TAS. L'hypothèse principale des chercheurs est que l'apprentissage de l'extinction vicariante contribuera à l'apprentissage de la sécurité et que l'ocytocine potentialisera l'apprentissage de l'extinction vicariante chez les patients atteints de TAS, par rapport aux témoins sains (HC). Les chercheurs testeront directement l'effet de l'ocytocine intranasale et du placebo correspondant sur les mécanismes cérébraux sous-jacents à l'apprentissage par extinction indirecte à l'aide d'une nouvelle tâche. 60 adultes atteints de TAS et 60 participants témoins en bonne santé effectueront une tâche qui comprend trois phases : (i) une procédure standard d'acquisition de la peur sociale dans un faux scanner, suivie de (ii) une extinction par procuration et (iii) une procédure de test de rétablissement de la peur, tout en étant scanné pendant l'imagerie par résonance magnétique fonctionnelle (fMRI). Les participants recevront de l'ocytocine ou un placebo avant la phase d'extinction. Les chercheurs mesureront également les réponses de conductance cutanée comme indice d'apprentissage dans chaque phase.

Type d'étude

Interventionnel

Inscription (Réel)

121

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • Washington
      • Seattle, Washington, États-Unis, 98195
        • University of Washington

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Critère d'intégration:

Pour l'échantillon clinique

  • Hommes et femmes de 18 à 45 ans
  • Les femmes doivent avoir des cycles menstruels réguliers et ne pas prendre de contraception orale
  • Diagnostic principal de trouble d'anxiété sociale

Pour un échantillon sain

  • Hommes et femmes de 18 à 45 ans
  • Les femmes doivent avoir des cycles menstruels réguliers et ne pas prendre de contraception orale
  • Aucun antécédent actuel ou à vie de troubles psychiatriques, neurologiques ou médicaux

Critère d'exclusion:

Pour tous les groupes

  • Grossesse ou allaitement
  • Résultat positif du test de dépistage de drogue dans l'urine
  • Antécédents de pathologie nasale
  • Utilisation actuelle de tout médicament psychotrope ou de stéroïdes
  • Trouble lié à l'utilisation de substances actives au cours des 6 derniers mois
  • Antécédents de maladies médicales graves ou de maladies endocriniennes non traitées
  • Antécédents de traumatisme crânien, de trouble neurologique ou d'intervention neurochirurgicale
  • Écran de résonance magnétique positive (MR)

Pour l'échantillon clinique

  • Diagnostics à vie de manie ou de trouble psychotique basés sur le Manuel diagnostique et statistique (DSM-5e éd.)
  • Idées suicidaires aiguës

Pour un échantillon sain

  • Diagnostic DSM-5 à vie de toute maladie médicale, neurologique ou psychiatrique

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Clinique
Ce groupe est composé d'individus présentant au moins des symptômes modérés de trouble d'anxiété sociale. Ce groupe recevra soit une administration d'ocytocine, soit un placebo (randomisation en aveugle).
Médicament: Oxytocin nasal spray or placebo
Single acute administration of 24 international units (IU) oxytocin or matching placebo
Comparateur placebo: Contrôles
Ce groupe se compose d'un échantillon sain d'individus (aucun diagnostic de manie ou de troubles psychotiques à vie). Ce groupe recevra soit une administration d'ocytocine, soit un placebo (randomisation en aveugle).
Médicament: Oxytocin nasal spray or placebo
Single acute administration of 24 international units (IU) oxytocin or matching placebo

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Neural Responses in the CS+R vs CS+S Contrast in the Insula During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Hippocampus During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Anterior Cingulate Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Ventromedial Prefrontal Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Anterior Cingulate Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Insula During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Hippocampus During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Amygdala During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the amygdala region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS- During Extinction
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS- stimuli during Extinction
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS+S During Extinction
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS+S stimuli during Extinction
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS+R During Extinction
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS+R stimuli during Extinction
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS- During Reinstatement
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS- stimuli during Reinstatement
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS+S During Reinstatement
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS+S stimuli during Reinstatement
immediately (45 minutes) after receiving drug
Skin Conductance Responses (SCR) to CS+R During Reinstatement
Délai: immediately (45 minutes) after receiving drug
mean skin conductance responses (SCR) for CS+R stimuli during Reinstatement
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Insula During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Amygdala During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the amygdala region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Ventromedial Prefrontal Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Hippocampus During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Anterior Cingulate Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Ventromedial Prefrontal Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during vicarious extinction (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Amygdala During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS- (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the amygdala region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Insula During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS- (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Hippocampus During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS- (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Anterior Cingulate Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS- (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Hippocampus During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during vicarious extinction (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS- Contrast in the Ventromedial Prefrontal Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS- (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Amygdala During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during vicarious extinction (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the amygdala region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Insula During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during vicarious extinction (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Ventromedial Prefrontal Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during vicarious extinction (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Anterior Cingulate Cortex During the Extinction Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during vicarious extinction (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Amygdala During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during fear reinstatement, which tests the return of fear (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the amygdala region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Insula During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the insula during fear reinstatement, which tests the return of fear (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the insula region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Hippocampus During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the hippocampus during fear reinstatement, which tests the return of fear (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the hippocampus region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Anterior Cingulate Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the anterior cingulate cortex during fear reinstatement, which tests the return of fear (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the anterior cingulate cortex region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+S vs CS- Contrast in the Ventromedial Prefrontal Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the ventromedial prefrontal cortex during fear reinstatement, which tests the return of fear (specifically for CS+S versus CS- conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. A lack of difference between these two task conditions is desirable, indicating processing both task conditions as safety cues.
immediately (45 minutes) after receiving drug
Neural Responses in the CS+R vs CS+S Contrast in the Ventromedial Prefrontal Cortex During the Reinstatement Phase
Délai: immediately (45 minutes) after receiving drug
Change in task-related blood oxygen level dependent (BOLD) responses in the amygdala during fear reinstatement, which tests for the return of fear (specifically for CS+R (reinforced) versus CS+S (non-reinforced) conditions). Changes in BOLD responses refer to differences in neural responses between these two task conditions, which were extracted from the ventromedial prefrontal cortex region of interest and estimated using a general linear model. Higher mean responses reflect greater discrimination (better able to distinguish between threat and safety cues) between the task conditions.
immediately (45 minutes) after receiving drug

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
réponses de conductance cutanée (SCR) à un signal éteint par procuration par rapport à un signal renforcé par procuration lors de la réintégration
Délai: immédiatement après l'intervention
SCR moyen pour CS- versus CS+
immédiatement après l'intervention

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Washington

Les enquêteurs

  • Chercheur principal: Angela Fang, PhD, University of Washington

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

26 juin 2023

Achèvement primaire (Réel)

30 septembre 2024

Achèvement de l'étude (Réel)

30 septembre 2024

Dates d'inscription aux études

Première soumission

10 juillet 2023

Première soumission répondant aux critères de contrôle qualité

26 juillet 2023

Première publication (Réel)

1 août 2023

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

11 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 juin 2026

Dernière vérification

1 mars 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • STUDY00013670

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner